Short Interest in Renalytix Plc (NASDAQ:RNLX) Drops By 15.3%

Renalytix Plc (NASDAQ:RNLX) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 673,700 shares, a decrease of 15.3% from the March 31st total of 795,200 shares. Based on an average daily volume of 1,830,000 shares, the short-interest ratio is presently 0.4 days.

Institutional Trading of Renalytix

Institutional investors have recently modified their holdings of the business. Pinnacle Associates Ltd. increased its holdings in Renalytix by 7.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 846,534 shares of the company’s stock worth $330,000 after acquiring an additional 60,572 shares during the period. Pentwater Capital Management LP increased its holdings in shares of Renalytix by 5.9% in the 3rd quarter. Pentwater Capital Management LP now owns 598,440 shares of the company’s stock worth $958,000 after buying an additional 33,440 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Renalytix in the 3rd quarter worth $547,000. 9.92% of the stock is currently owned by hedge funds and other institutional investors.

Renalytix Stock Performance

Shares of RNLX stock opened at $0.69 on Wednesday. The company has a market capitalization of $43.79 million, a price-to-earnings ratio of -1.54 and a beta of 3.03. Renalytix has a 52-week low of $0.24 and a 52-week high of $4.04. The company has a 50-day simple moving average of $0.88 and a two-hundred day simple moving average of $0.70.

Renalytix (NASDAQ:RNLX) last announced its quarterly earnings results on Wednesday, February 14th. The company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). The company had revenue of $0.71 million for the quarter, compared to analysts’ expectations of $0.70 million. Renalytix had a negative net margin of 1,736.47% and a negative return on equity of 1,008.88%.

Renalytix Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.